Technology

Major depressive disorder affects approximately 4.7% world population annually and 1 in 3 do not recover with medications or therapy. For treatment-resistant depression (TRD), electroconvulsive therapy (ECT) is effective (60-70% remission), but hampered by the need for anesthesia, significant cognitive side effects, and high stigma. Less than 1% of TRD population receive ECT annually.

Repetitive transcranial magnetic stimulation (rTMS) is an emerging therapeutic brain stimulation technique that does not require anesthesia, has no cognitive side effects, and is widely accepted by patients. rTMS is currently administered by a technician or nurse in an outpatient clinical setting. The potency and efficacy of conventional biphasic rTMS (45-55% response, 30-35% remission) falls between medications and ECT, but rTMS offers the advantages of high tolerability and accessibility.

NeuroQore monophasic rTMS system with an improved remission rate has potential to be a disruptive innovation that results in improved health care worldwide. NeuroQore is looking to effectively integrate into existing health-care facilities and coordinated with ongoing treatments as a complement to medications and therapy.